Vinod Ganju

8.2k total citations · 1 hit paper
94 papers, 2.7k citations indexed

About

Vinod Ganju is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Vinod Ganju has authored 94 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Vinod Ganju's work include Colorectal Cancer Treatments and Studies (26 papers), Cancer Treatment and Pharmacology (20 papers) and Lung Cancer Treatments and Mutations (18 papers). Vinod Ganju is often cited by papers focused on Colorectal Cancer Treatments and Studies (26 papers), Cancer Treatment and Pharmacology (20 papers) and Lung Cancer Treatments and Mutations (18 papers). Vinod Ganju collaborates with scholars based in Australia, United States and New Zealand. Vinod Ganju's co-authors include D. Neil Watkins, Muhammad Alamgeer, Mark Jeffery, Donald Richards, Charles S. Fuchs, Rafal Wierzbicki, Edith P. Mitchell, John L. Marshall, José Barrueco and Raoudha Soufi‐Mahjoubi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Immunology.

In The Last Decade

Vinod Ganju

89 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study

2007 665 citations Vinod Ganju et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Vinod Ganju

Since Specialization

Citations

This map shows the geographic impact of Vinod Ganju's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vinod Ganju with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vinod Ganju more than expected).

Fields of papers citing papers by Vinod Ganju

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vinod Ganju. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vinod Ganju. The network helps show where Vinod Ganju may publish in the future.

Co-authorship network of co-authors of Vinod Ganju

This figure shows the co-authorship network connecting the top 25 collaborators of Vinod Ganju. A scholar is included among the top collaborators of Vinod Ganju based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vinod Ganju. Vinod Ganju is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors 2025 ·British Journal of Cancer ·Daphne Day, Vinod Ganju, Ki Y. Chung, Lu Si, Lili Mao, Morteza Aghmesheh, Robert J. Hoyer, (unknown), (unknown), (unknown), Qiaoyang Lu, Chengjun Jiang, (unknown), (unknown), Jun Guo	3
2	A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC). 2024 ·Journal of Clinical Oncology ·(unknown), Lin Shen, Sumitra Ananda, Dan Cao, Catherine Han, Jermaine Coward, (unknown), Wei Li, (unknown), Chih‐Hung Hsu, Adnan Nagrial, (unknown), Vinod Ganju, Xiaobing Chen, Deirdre Jill Cohen, Rajiv Kumar, Li-Yuan Bai, Ying Yuan, (unknown)	1
3	P3.12D.09 Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous Non-Small Cell Lung Cancer 2024 ·Journal of Thoracic Oncology ·(unknown), Ganessan Kichenadasse, Gary Richardson, Samantha Bowyer, Vladimir Andelkovic, Vinod Ganju, Alvin Tan, (unknown), David M. Thomas, (unknown), Konrad Paszkiewicz, Patrick Ingram, Jerome D. Boyd‐Kirkup, (unknown)	0
4	464 (PB452): Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells 2024 ·European Journal of Cancer ·Timothy Wyant, (unknown), Drew Rasco, Andrew Haydon, John D. Powderly, Andrew Weickhardt, (unknown), Paul de Souza, Vinod Ganju, Siwen Hu‐Lieskovan, Ganessan Kichenadasse, Jiaqi Tang, Louise Richards, (unknown), Ido Amit, Yishai Ofran, Jim Vasselli	0
5	A STAT3–STING–IFN axis controls the metastatic spread of small cell lung cancer 2024 ·Nature Immunology ·(unknown), (unknown), W. Samantha N. Jayasekara, Eveline D. de Geus, (unknown), (unknown), (unknown), Nicole A. de Weerd, Antony Y. Matthews, Michael P. Gantier, Jesse J. Balic, (unknown), Daniel J. Garama, Paul J. Hertzog, Vinod Ganju, D. Neil Watkins, Jason E. Cain, Daniel J. Gough	12
6	Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells 2023 ·Clinical Cancer Research ·Vinod Ganju, Gavin Marx, Scott Pattison, Nancy B. Amaro-Mugridge, Jing Zhao, Bryan R.G. Williams, Jennifer A. MacDiarmid, Himanshu Brahmbhatt	6
7	1028P Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors 2023 ·Annals of Oncology ·Daphne Day, Vinod Ganju, Ki Y. Chung, Lu Si, Limin Mao, Morteza Aghmesheh, Robert J. Hoyer, (unknown), Song Zeng, (unknown), Cui Jiang, Renhai Feng, (unknown), Jin Guo	4
8	700P First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors 2023 ·Annals of Oncology ·Adam Cooper, Vladimir Andelkovic, Kate Wilkinson, Vinod Ganju, Joanne Lundy, Ming Hong, (unknown), Lingwei Meng, Bin Shen, Han Li, Yao Li, Minghui Zhang, Jermaine Coward	2
9	656MO The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study 2023 ·Annals of Oncology ·Herui Yao, Min‐Hee Ryu, Jong Moon Park, Mark Voskoboynik, Jee Hyun Kim, Kai Liu, Minal Barve, Ana Acuña-Villaorduña, S-A. Im, A.C. Roy, (unknown), C-J. Yen, Jian Zhang, Vinod Ganju, Liangliang Wu, Min Yan, Linlin Bao, Yutong Zhao, Song Rong, Erwei Song	5
10	MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat 2023 ·Journal of Experimental & Clinical Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Daniel J. Garama, Muhammad Alamgeer, (unknown), Michael DeVeer, Vinod Ganju, D. Neil Watkins, Jason E. Cain, Daniel J. Gough	21
11	A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer 2017 ·Investigational New Drugs ·Muhammad Alamgeer, D. Neil Watkins, (unknown), Beena Kumar, Daniel J. Gough, Ben Markman, Vinod Ganju	35
12	O-019 SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment 2015 ·Annals of Oncology ·Guy A. Van Hazel, Volker Heinemann, Navesh Sharma, Michael Findlay, Jens Ricke, Marc Peeters, David Pérez, Bridget A. Robinson, A. H. Strickland, (unknown), (unknown), Hendrik Kroening, Ido Wolf, Vinod Ganju, Euan Walpole, Éveline Boucher, Thomas Tichler, Val Gebski, Mark Van Buskirk, Peter Gibbs	0
13	Genomic Characterisation of Small Cell Lung Cancer Patient-Derived Xenografts Generated from Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Specimens 2014 ·PLoS ONE ·Tracy L. Leong, Kieren D. Marini, Fernando J. Rossello, (unknown), Prudence A. Russell, Zdenka Prodanovic, Beena Kumar, Vinod Ganju, Muhammad Alamgeer, Louis Irving, Daniel Steinfort, Craig D. Peacock, Jason E. Cain, Anette Szczepny, D. Neil Watkins	26
14	Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. 2013 ·PubMed ·Arlene Chan, Pierfranco Conté, Luboš Petruželka, N. Tubiana-Mathieu, Vinod Ganju, Antonio Llombart‐Cussac, Marc Espié, F. Majois, Miguel Gil Gil, Nathalie Vaissière, G. Villanova	6
15	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study 2010 ·Journal of Clinical Oncology ·Niall C. Tebbutt, Kate Wilson, Val Gebski, Michelle M. Cummins, Diana Zannino, Guy A. Van Hazel, Bridget A. Robinson, A. Broad, Vinod Ganju, Stephen P. Ackland, Garry Forgeson, David Cunningham, Mark Saunders, Martin R. Stockler, (unknown), John Zalcberg, R. J. Simes, Timothy Price	315
16	The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET 2010 ·Breast Cancer Research ·Michal Schneider, Stewart Hart, Jane Fox, Peter Midolo, John Stuckey, Michael S. Hofman, Vinod Ganju	29
17	A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer 2008 ·British Journal of Cancer ·Michael Michael, Timothy Price, Samuel Y. Ngan, Vinod Ganju, A. H. Strickland, (unknown), (unknown), A. Milner, (unknown), A Matera, John Zalcberg, Trevor Leong	4
18	Region‐specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma 1995 ·Genes Chromosomes and Cancer ·(unknown), Vinod Ganju, (unknown)	84
19	Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers 1994 ·Cancer ·Vinod Ganju, Robert B. Jenkins, Judith R. OʼFallon, B. W. Scheithauer, David Ransom, (unknown), David W. Kimmel	71
20	PROTEIN‐LOSING ENTEROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS 1988 ·Australian and New Zealand Journal of Medicine ·Simon Edmunds, Vinod Ganju, B. R. Beveridge, Martyn A. French, Marina Quinlan	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact